Stephen Steele, MD
Gastroenterology · Texarkana, TXNPI 1376837344
Payments from drug & device makers
Across 561 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Takeda Pharmaceuticals U.S.A., Inc.$975
- Gilead$825
- Johnson & Johnson$781
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$542
- Pfizer$350
- plus $2K from 28 others
What the payments were for
- Food & beverage$9,24299%
- Education$671%
- Gifts$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 232 | $3,502 |
| Takeda Pharmaceuticals U.S.A., Inc. | 70 | $975 |
| Gilead | 54 | $825 |
| Johnson & Johnson | 41 | $781 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $542 |
| Pfizer | 26 | $350 |
| Phathom Pharmaceuticals, Inc. | 14 | $350 |
| Ardelyx, Inc. | 19 | $324 |
| Sanofi | 11 | $285 |
| Evoke Pharma, Inc. | 3 | $214 |
| Intercept Pharmaceuticals, Inc. | 9 | $165 |
| Lilly USA, LLC | 8 | $146 |
| Merck | 7 | $118 |
| Braintree Laboratories, Inc. | 6 | $100 |
| Bristol Myers Squibb | 4 | $64 |
| Redhill Biopharma Inc. | 3 | $55 |
| Madrigal Pharmaceuticals | 3 | $53 |
| Amgen | 3 | $47 |
| Nestle Healthcare Nutrition Inc. | 2 | $41 |
| UCB, Inc. | 3 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Medtronic | 2 | $38 |
| Ironwood Pharmaceuticals, Inc | 3 | $35 |
| Ipsen Biopharmaceuticals, Inc | 2 | $35 |
| Boston Scientific | 1 | $35 |
| AstraZeneca | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 1 | $24 |
| Novo Nordisk | 1 | $21 |
| Mauna Kea Technologies, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Enterra Medical, Inc. | 1 | $16 |
| Celltrion USA Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Organon | 3 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,323 in reported general payments places this provider in the 70th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 13 | $180,898 |
| Humira(Cf) PenAdalimumab | 13 | $86,913 |
| LinzessLinaclotide | 73 | $63,262 |
| XifaxanRifaximin | 16 | $42,402 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 313 | $19,269 |
| OzempicSemaglutide | 13 | $14,624 |
| MotegrityPrucalopride Succinate | 23 | $11,540 |
| Dexlansoprazole DrDexlansoprazole | 43 | $10,928 |
| Sucralfate | 81 | $4,598 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 21 | $3,404 |
| Omeprazole | 282 | $3,275 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 14 | $2,365 |
| Pantoprazole Sodium | 151 | $1,278 |
| Azathioprine | 28 | $793 |
| Lubiprostone | 16 | $786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $3,502 | $63,26273 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $542 | $42,40216 claims |
| Novo NordiskOzempic | $21 | $14,62413 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $975 | $11,54023 claims |
| Braintree Laboratories, Inc.Sutab | $100 | $3,40421 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $24 | $2,36514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Texarkana
- Eric LawitzSan Antonio$59.5M
- George DuvallTyler$17.5M
- John FordtranDallas$9.9M
- Timothy RitterSouthlake$7.7M
- Parvez MantryDallas$6.4M
- Mazen NoureddinHouston$6.1M
- Nadege GunnWaco$5.7M
- Michael BrownDallas$5.5M
- James MaherHouston$5.3M
- Stephen HarrisonLive Oak$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.